53 Analysis of translational challenges across 19 brain tumour therapeutic development programmes: Insights from the BTR-NTA accelerator

Clicks: 20
ID: 326764
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #139 of 286 articles by views in journal of neuro-oncology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 286 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Introduction Development of novel therapies for brain tumours faces high attrition rates, with few programmes reaching approval. This thematic analysis synthesises translational challenges identified through the Brain Tumour Research Novel Therapeutics Accelerator (BTR-NTA), an international multidisciplinary programme providing structured expert guidance to accelerate novel brain tumour treatments toward clinical application. Methods Between 2023 and 2025, BTR-NTA received 33 applications from academic and industry groups developing novel brain tumour therapies. Nineteen programmes were selected based on scientific merit and clinical potential and received up to 240 hours of multidisciplinary input across preclinical, clinical, regulatory, commercialisation, and patient advocacy domains. A structured analysis of feedback reports from 19 programmes was conducted to identify recurring translational challenges. Themes were stratified by applicant type, development stage and modality. Results Analysis identified five recurring translational challenges: (1) all programmes required guidance on defining data packages to support milestone decisions (e.g., IND-enabling studies, go/no-go criteria); (2) 95% had insufficient CNS penetration or tumour-site distribution data from clinically relevant disease models; (3) all programmes needed guidance on timing and scope of regulatory engagement; (4) 79% lacked manufacturing readiness despite scientific maturity; and (5) 53% required support developing patient and public involvement strategies. Six of 11 eligible programmes (55%) completed a one-year follow-up survey. All respondents had adapted their development strategy based on BTR-NTA guidance and secured follow-on funding from governmental, charitable, or venture capital sources. Conclusions There appear to be systemic translational challenges that risk delaying progression into the clinic of potential therapies built on robust scientific data. Earlier expert guidance may accelerate therapy development and improve success rates. Wider dissemination of these insights may support improvement in translational pathways across the brain tumour therapeutic development landscape.
Reference Key
openalex_W7204469468 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Kate Munro, Eloise Lines, Nicky Huskens, Katie Bushby, Karen Noble, Paul Brennan, Helen Bulbeck, Petra Hamerlik, Darren Hargrave, Edward Kaye, Dione Kobayashi, Ryan Mathew, Javad Nazarian, Ruman Rahman, Artie Romero, Erik Sulman, Juanita Lopez, Kanneboyina Nagaraju
Are you one of these authors? Claim your profile
Journal journal of neuro-oncology
Year 2026
DOI
10.1093/neuonc/noag172.086
URL
https://academic.oup.com/neuro-oncology/article-pdf/28/Supplement_1/noag172.086/70805927/noag172.086.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.